In recent years, the healthcare sector has witnessed a series of significant developments in the field of diabetology. One of these is the entry into the market of long-established companies which, in terms of structure and financial autonomy, are start-ups but with many years of experience and history behind them.

In March 2024, Embecta, an American multinational company specializing in the production and marketing of medical technologies for insulin delivery for the treatment of diabetes, opened its Italian headquarters in MIND Milano Innovation District.

The discovery of insulin was a milestone in the history of medicine and diabetes care. During the 19th century, physiologists understood that the pancreas played a key role in human metabolism, but they were unable to understand its direct role in diabetes. It was not until 1921 that the breakthrough came, thanks to Canadian scientists Frederick G. Banting, Charles Best, and James Bertram Collip. In 1924, Becton Dickinson made the first insulin syringe available.

Embecta was founded in Italy as a spin-off of Becton Dickinson, a US MedTech giant that had already decided in 2022 to give shape and substance to a global operation. Embecta's entry into the Italian diabetes market has the clear objective of continuing to offer innovative solutions of undisputed quality, as it has always done since 1924.

Embecta, carrying on the legacy of Becton Dickinson, which we still find today in the company's brand name, is different from other companies in that it is a start-up with 100 years of experience behind it.

From MIND, through its General Manager Roberto Bettin, EMBECTA leads the entire Southern European cluster comprising Spain, Italy, Greece, and Portugal. "Competition in the diabetes sector is intense, with other companies offering similar but far from identical devices. Embecta must continue to innovate and stand out through the quality that has always set it apart, and what better place to do so than at MIND," explains Roberto Bettin. "We must prepare for our next 100 years so that institutions, patients, and the scientific community can work together with companies like Embecta because the future belongs to everyone and health can never take a back seat, even in a hundred years."